Compare Illumina, Inc. (ILMN) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Liberty Global Ltd Class C — how do they compare? Illumina, Inc. trades at $275.97 (market cap $39.95B), while Liberty Global Ltd Class C trades at $8.45 (market cap $3.06B). The key difference: Illumina, Inc. is far larger — about 13.1× Liberty Global Ltd Class C's market cap, and Illumina, Inc. is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Liberty Global Ltd Class C for 21 Days on average.
| ILMN | LBTYK | |
|---|---|---|
Market Cap | $39.95B | $3.06B |
Volume | 3,169,503 | 2,508,956 |
Sector | Health | Media |
52-Week High | $293.69 | $12.67 |
52-Week Low | $91.00 | $8.75 |
Typical Hold Time | 83 Days | 21 Days |
Enterprise Value | $41.31B | $9.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
